Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


SERVIER and Crystax Pharmaceuticals sign research collaboration


Barcelona, 9th September, 2005.
SERVIER, the leading French drug company, and CrystaX Pharmaceuticals, the Spanish biotech company, have entered into an agreement for the structure determination of an undisclosed target complexed to various lead candidates. The research contract establishes that CrystaX will provide its expertise and capabilities in high-throughput protein expression, purification and X-ray crystallography to elucidate the 3D crystal structure of target-ligand complexes. Such information will allow SERVIER to accelerate its drug discovery efforts. Under the agreement, SERVIER will provide CrystaX with an upfront payment followed by milestone achievements.


About SERVIER
Servier is the largest privately-owned pharmaceutical company in France. It is the second ranked French drug group worldwide and the fourteenth in the European ranking of drug companies. Servier was established in 1954 by founder and current Chairman, Jacques Servier, M.D. The Servier Group allocates approximately 25% of its turnover to R & D. The Group has 16,000 employees worlwide includind 2,500 in R & D The Servier Group has 70 subsidiaries and markets it products in 140 countries, primarily for the treatment of diabetes, cardiovascular disease, neuropsychiatric disorders, cancer, and bone and joint diseases.
For further information, please visit the Servier website: www.servier.com

About CrystaX Pharmaceuticals S.L.
CrystaX is a leading structure based drug discovery company located at the Barcelona Science Park. The company was formed in 2002 and provides a wide range of research services to the pharmaceutical industry with the aim of developing NCE’s and lead candidates. Crystax’s integrated platform technology includes gene cloning, high-throughput protein expression and purification, X-ray crystallography, NMR and fragment screening, an emerging technology to identify novel lead structures for drug development.
For further information, please visit the Crystax website: www.crystax.com


Publisher Contact Information:

Crystax Pharmaceuticals S.L.
+34 934034787
egasol@crystax.com

Company profile of Crystax Pharmaceuticals S.L.
Past press releases of Crystax Pharmaceuticals S.L..

Data


27,722
Tech investments
From our Online Data Service
17,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 21€50.0MKnowledge management
Dec 20€16.0MSemiconductors
Dec 17€18.0MOther Computers & Electronics
Dec 17€5.2MBiotechnology
Dec 17€17.0MBusiness applications
Dec 15€17.0ME-Commerce
Dec 4€3.3MNanotechnology

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Sep 30
TetaVi
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Mar 31
CompPair
the fit allocates chf 100'000 to comppair technologies

Jan 29
Yumpingo
yumpingo raises $10m to transform guest experiences in restaurants





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.